

Patrick J Mcgrath

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1061379/patrick-j-mcgrath-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

18,396
citations

54
h-index

135
g-index

175
ext. papers

21,807
ext. citations

6.9
avg, IF

5.64
L-index

#	Paper	IF	Citations
169	Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1905-17	11.9	3098
168	Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>American Journal of Psychiatry</i> , 2006 , 163, 28-40	11.9	2607
167	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013 , 45, 984-94	36.3	1628
166	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. <i>Nature Genetics</i> , 2018 , 50, 668-681	36.3	1301
165	A mega-analysis of genome-wide association studies for major depressive disorder. <i>Molecular Psychiatry</i> , 2013 , 18, 497-511	15.1	853
164	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004 , 25, 119-42		725
163	A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1519-30; quiz 1665	11.9	380
162	Harmonization of cortical thickness measurements across scanners and sites. <i>NeuroImage</i> , 2018 , 167, 104-120	7.9	286
161	Regional brain asymmetries in major depression with or without an anxiety disorder: a quantitative electroencephalographic study. <i>Biological Psychiatry</i> , 1997 , 41, 939-48	7.9	272
160	A genomewide association study of citalopram response in major depressive disorder. <i>Biological Psychiatry</i> , 2010 , 67, 133-8	7.9	251
159	Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 739-52	11.9	246
158	Tranlycypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1531-41; quiz 1666	11.9	244
157	Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. <i>Molecular Psychiatry</i> , 2011 , 16, 202-15	15.1	209
156	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1161-1172	11.9	203
155	Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. <i>Biological Psychiatry</i> , 2008 , 63, 1177-9		200
154	Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. <i>Archives of General Psychiatry</i> , 1996 , 53, 232-40		187
153	Antidepressants normalize the default mode network in patients with dysthymia. <i>JAMA Psychiatry</i> , 2013 , 70, 373-82	14.5	185

152	Sequence analysis of the serotonin transporter and associations with antidepressant response. <i>Biological Psychiatry</i> , 2005 , 58, 374-81	7.9	185
151	Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. <i>Biological Psychiatry</i> , 2001 , 49, 416-25	7.9	174
150	Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. <i>American Journal of Psychiatry</i> , 2009 , 166, 599-607	11.9	171
149	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. <i>Journal of Psychiatric Research</i> , 2016 , 78, 11-23	5.2	153
148	Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. <i>Archives of General Psychiatry</i> , 1998 , 55, 153-60		140
147	Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. <i>Biological Psychiatry</i> , 2007 , 61, 734-42	7.9	133
146	Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. <i>PLoS ONE</i> , 2008 , 3, e1872	3.7	129
145	Columbia Atypical Depression: A Subgroup of Depressives with Better Response to MAOI than to Tricyclic Antidepressants or Placebo. <i>British Journal of Psychiatry</i> , 1993 , 163, 30-34	5.4	127
144	Current source density measures of electroencephalographic alpha predict antidepressant treatment response. <i>Biological Psychiatry</i> , 2011 , 70, 388-94	7.9	114
143	Are there differences between women's and men's antidepressant responses?. <i>American Journal of Psychiatry</i> , 2002 , 159, 1848-54	11.9	112
142	Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. <i>Drug and Alcohol Dependence</i> , 2009 , 99, 248-60	4.9	109
141	A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1161-1172	11.9	100
140	Atypical Depression: A Valid Clinical Entity?. <i>Psychiatric Clinics of North America</i> , 1993 , 16, 479-495	3.1	95
139	Imipramine treatment of cocaine abuse: possible boundaries of efficacy. <i>Drug and Alcohol Dependence</i> , 1995 , 39, 185-95	4.9	91
138	Right brain, left brain in depressive disorders: Clinical and theoretical implications of behavioral, electrophysiological and neuroimaging findings. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 78, 178-191	8.1	87
137	Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. <i>American Journal of Psychiatry</i> , 2006 , 163, 73-8	11.9	83
136	Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. <i>American Journal of Psychiatry</i> , 2006 , 163, 59-66	11.9	83
135	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2018 , 75, 547-554	14.5	80

134	Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1847-55	4.6	80
133	When should a trial of fluoxetine for major depression be declared failed?. <i>American Journal of Psychiatry</i> , 2003 , 160, 734-40	11.9	75
132	Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. <i>Journal of General Internal Medicine</i> , 2008 , 23, 551-60	4	74
131	Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 1-10	1.9	73
130	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. <i>Psychological Medicine</i> , 2019 , 49, 1118-1127	6.9	72
129	Predictors of relapse in a prospective study of fluoxetine treatment of major depression. <i>American Journal of Psychiatry</i> , 2006 , 163, 1542-8	11.9	72
128	Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. <i>American Journal on Addictions</i> , 2006 , 15, 278-85	3.7	70
127	Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment. <i>Psychiatry Research</i> , 1988 , 25, 213-22	9.9	69
126	An electroencephalographic signature predicts antidepressant response in major depression. <i>Nature Biotechnology</i> , 2020 , 38, 439-447	44.5	68
125	Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. <i>Archives of General Psychiatry</i> , 1998 , 55, 334-43		68
124	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. <i>American Journal of Psychiatry</i> , 2015 , 172, 881-91	11.9	67
123	Reduced brain responses to novel sounds in depression: P3 findings in a novelty oddball task. <i>Psychiatry Research</i> , 2009 , 170, 218-23	9.9	67
122	Childhood trauma history is linked to abnormal brain connectivity in major depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8582-8590	11.5	66
121	Brain ERPs of depressed patients to complex tones in an oddball task: Relation of reduced P3 asymmetry to physical anhedonia. <i>Psychophysiology</i> , 1998 , 35, 54-63	4.1	65
120	Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. <i>Comprehensive Psychiatry</i> , 2005 , 46, 81-9	7.3	65
119	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. <i>Neuropsychopharmacology</i> , 2016 , 41, 454-63	8.7	62
118	Adverse Reactions to Monoamine Oxidase Inhibitors. Part II. Treatment Correlates and Clinical Management. <i>Journal of Clinical Psychopharmacology</i> , 1985 , 5, 2??9	1.7	61
117	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2010 , 107, 161-70	4.9	59

116	Acceptability of second-step treatments to depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 753-60	11.9	56
115	Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 565-73	11.9	52
114	Neurocognitive predictors of antidepressant clinical response. <i>Journal of Affective Disorders</i> , 2014 , 166, 108-14	6.6	51
113	Dr. Quitkin and Associates Reply. <i>American Journal of Psychiatry</i> , 1988 , 145, 1322-b-1322	11.9	48
112	Adverse Reactions to Monoamine Oxidase Inhibitors. Part I. A Comparative Study. <i>Journal of Clinical Psychopharmacology</i> , 1984 , 4, 270-278	1.7	46
111	A genome-wide association study of a sustained pattern of antidepressant response. <i>Journal of Psychiatric Research</i> , 2013 , 47, 1157-65	5.2	45
110	Defining the boundaries of atypical depression: evidence from the HPA axis supports course of illness distinctions. <i>Journal of Affective Disorders</i> , 2005 , 86, 161-7	6.6	45
109	Treatment of maternal depression in a medication clinical trial and its effect on children. <i>American Journal of Psychiatry</i> , 2015 , 172, 450-9	11.9	43
108	Do atypical features affect outcome in depressed outpatients treated with citalopram?. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 15-30	5.8	41
107	Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. <i>Psychiatry Research</i> , 2008 , 161, 116-20	9.9	39
106	Baseline characteristics of 10-day placebo washout responders in antidepressant trials. <i>Psychiatry Research</i> , 1987 , 21, 9-22	9.9	39
105	Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. <i>Psychophysiology</i> , 2017 , 54, 34-50	4.1	38
104	Dichotic listening tests of functional brain asymmetry predict response to fluoxetine in depressed women and men. <i>Neuropsychopharmacology</i> , 2004 , 29, 1752-61	8.7	37
103	Atypical depression: Enhanced right hemispheric dominance for perceiving emotional chimeric faces.. <i>Journal of Abnormal Psychology</i> , 2002 , 111, 446-454	7	37
102	Predictive Value of Symptoms of Atypical Depression. <i>Journal of Clinical Psychopharmacology</i> , 1992 , 12, 197-202	1.7	37
101	Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. <i>Journal of Clinical Psychiatry</i> , 2000 , 61, 518-24	4.6	37
100	DSM-IV depression with atypical features: is it valid?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2625-32	8.7	36
99	Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features?. <i>Neuropsychopharmacology</i> , 2002 , 26, 237-45	8.7	36

98	A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. <i>International Journal of Eating Disorders</i> , 1994 , 15, 1-9	6.3	36
97	Sleep of atypical depressives. <i>Journal of Affective Disorders</i> , 1985 , 8, 61-7	6.6	36
96	Pattern recognition of magnetic resonance imaging-based gray matter volume measurements classifies bipolar disorder and major depressive disorder. <i>Journal of Affective Disorders</i> , 2018 , 227, 498-505	6.6	36
95	Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. <i>Journal of Affective Disorders</i> , 2002 , 71, 113-20	6.6	35
94	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2016 , 33, 56-65	8.4	32
93	Gepirone Treatment of Atypical Depression. <i>Journal of Clinical Psychopharmacology</i> , 1994 , 14, 347-352	7.1	32
92	Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 214-7	2.2	30
91	Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 670-6	4.6	30
90	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. <i>Neuropsychopharmacology</i> , 2018 , 43, 2221-2230	8.7	29
89	Left hemisphere dysfunction during verbal dichotic listening tests in patients who have social phobia with or without comorbid depressive disorder. <i>American Journal of Psychiatry</i> , 2004 , 161, 72-8	11.9	29
88	Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 707-15	4.6	29
87	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. <i>Psychotherapy and Psychosomatics</i> , 2018 , 87, 285-295	9.4	28
86	Abnormal functional brain asymmetry in depression: evidence of biologic commonality between major depression and dysthymia. <i>Psychiatry Research</i> , 2012 , 196, 250-4	9.9	28
85	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010 , 260, 145-50	5.1	27
84	The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study. <i>Lancet Psychiatry</i> , 2019 , 6, 667-674	23.3	26
83	Predictors of therapeutic response to treatments for depression: a review of electrophysiologic and dichotic listening studies. <i>CNS Spectrums</i> , 1999 , 4, 30-6	1.8	26
82	Placebo run-in period in studies of depressive disorders. Clinical, heuristic and research implications. <i>British Journal of Psychiatry</i> , 1998 , 173, 242-8	5.4	26
81	Combination antidepressant therapy for major depressive disorder: speed and probability of remission. <i>Journal of Psychiatric Research</i> , 2014 , 52, 7-14	5.2	25

80	Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. <i>Psychiatric Services</i> , 2011 , 62, 1167-79	3.3	25
79	Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. <i>Neuron</i> 45, 11-16. <i>Neuron</i> , 2005 , 48, 702-3; author reply 705-6	13.9	25
78	Development and evaluation of a multimodal marker of major depressive disorder. <i>Human Brain Mapping</i> , 2018 , 39, 4420-4439	5.9	23
77	EEG hemispheric asymmetries during cognitive tasks in depressed patients with high versus low trait anxiety. <i>Clinical EEG and Neuroscience</i> , 2010 , 41, 196-202	2.3	23
76	Efficacy of desipramine in endogenomorphically depressed patients. <i>Journal of Affective Disorders</i> , 1980 , 2, 165-76	6.6	23
75	Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 365-9	1.7	22
74	Study duration in antidepressant research: advantages of a 12-week trial. <i>Journal of Psychiatric Research</i> , 1986 , 20, 211-6	5.2	22
73	Monoamine oxidase inhibitors in bipolar endogenous depressives. <i>Journal of Clinical Psychopharmacology</i> , 1981 , 1, 70-4	1.7	22
72	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2018 , 84, 563-573	7.9	22
71	The management of treatment resistance in depressed patients with substance use disorders. <i>Psychiatric Clinics of North America</i> , 1996 , 19, 311-27	3.1	21
70	Can people with nonsevere major depression benefit from antidepressant medication?. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 518-25	4.6	21
69	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorder		21
68	A comparison of structural connectivity in anxious depression versus non-anxious depression. <i>Journal of Psychiatric Research</i> , 2017 , 89, 38-47	5.2	20
67	Do age of onset and course of illness define biologically distinct groups within atypical depression?. <i>Journal of Abnormal Psychology</i> , 2003 , 112, 253-62	7	20
66	Lactate provocation of panic attacks in depressed outpatients. <i>Psychiatry Research</i> , 1988 , 25, 41-7	9.9	19
65	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2019 , 85, 872-880	7.9	19
64	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. <i>Magnetic Resonance Imaging</i> , 2018 , 45, 26-33	3.3	18
63	Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study. <i>Contemporary Clinical Trials Communications</i> , 2017 , 6, 22-30	1.8	17

62	A reappraisal of atypical depression. <i>American Journal of Psychiatry</i> , 2003 , 160, 798-800; author reply 800-1	11.9	17
61	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. <i>PLoS ONE</i> , 2015 , 10, e0126326	3.7	17
60	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. <i>Molecular Psychiatry</i> , 2020 , 25, 1526-1536	15.1	17
59	Current concepts in the treatment of depression in alcohol-dependent patients. <i>Psychiatric Clinics of North America</i> , 2000 , 23, 695-711, V	3.1	16
58	A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 984-91	4.6	16
57	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. <i>Nature Human Behaviour</i> , 2019 , 3, 1319-1331	12.8	15
56	A comparative study of the pituitary TSH response to thyrotropin in outpatient depressives. <i>Psychiatry Research</i> , 1984 , 12, 185-93	9.9	15
55	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. <i>Clinical EEG and Neuroscience</i> , 2019 , 50, 3-12	2.3	15
54	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017 , 2, 138-148	3.4	14
53	Follow-up of Patients Who Improved During Placebo Washout. <i>Journal of Clinical Psychopharmacology</i> , 1986 , 6, 274-278	1.7	14
52	Placebo-controlled study of mianserin in depressed outpatients. <i>Neuropsychobiology</i> , 1985 , 14, 128-32	4	14
51	Do tricyclic responders have different brain laterality?. <i>Journal of Abnormal Psychology</i> , 1999 , 108, 707-710	1	13
50	Discovery and replication of cerebral blood flow differences in major depressive disorder. <i>Molecular Psychiatry</i> , 2020 , 25, 1500-1510	15.1	13
49	Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry. <i>Psychiatry Research</i> , 2007 , 153, 137-43	9.9	12
48	Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 289-91	1.7	12
47	Association of Whole-Genome and NETRIN1 Signaling Pathway-Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019 , 4, 91-100	3.4	12
46	Cortical thickness is not associated with current depression in a clinical treatment study. <i>Human Brain Mapping</i> , 2017 , 38, 4370-4385	5.9	11
45	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. <i>Biological Psychiatry</i> , 2021 ,	7.9	11

44	Atypical depression: enhanced right hemispheric dominance for perceiving emotional chimeric faces. <i>Journal of Abnormal Psychology</i> , 2002 , 111, 446-54	7	11
43	Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. <i>Annals of General Psychiatry</i> , 2010 , 9, 10	3.4	10
42	Variants in PDE11A and PDE1A are not associated with citalopram response. <i>Molecular Psychiatry</i> , 2007 , 12, 1061-3	15.1	10
41	Predictors of Antidepressant Response in Depressed Alcoholic Patients. <i>American Journal on Addictions</i> , 1996 , 5, 308-312	3.7	10
40	Mianserin versus amitriptyline for depression: a double-blind 6-week trial. <i>Neuropsychobiology</i> , 1984 , 12, 224-8	4	10
39	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008 , 6, 128-142	1.1	9
38	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. <i>Biological Psychiatry</i> , 2020 , 87, 419-430	7.9	9
37	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. <i>Journal of Psychopharmacology</i> , 2019 , 33, 185-193	4.6	8
36	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EClinicalMedicine</i> , 2019 , 10, 32-41	11.3	8
35	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. <i>Biological Psychiatry</i> , 2020 , 88, 657-667	7.9	8
34	Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?. <i>Journal of Psychiatric Practice</i> , 2009 , 15, 337-45	1.3	8
33	Deficits of white matter axial diffusivity in bipolar disorder relative to major depressive disorder: No relationship to cerebral perfusion or body mass index. <i>Bipolar Disorders</i> , 2020 , 22, 296-302	3.8	8
32	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018 , 102, 207-215	5.2	7
31	Cortisol response to dextroamphetamine stimulation in depressed outpatients. <i>Psychiatry Research</i> , 1984 , 12, 195-206	9.9	7
30	Effects of imipramine and phenelzine on plasma PEA levels. <i>Psychiatry Research</i> , 1988 , 26, 239	9.9	6
29	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. <i>Journal of Affective Disorders</i> , 2019 , 245, 1070-1078	6.6	6
28	Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. <i>Journal of Affective Disorders</i> , 2017 , 210, 258-264	6.6	5
27	Lateralization for speech predicts therapeutic response to cognitive behavioral therapy for depression. <i>Psychiatry Research</i> , 2015 , 228, 606-11	9.9	4

26	Is duloxetine effective treatment for depression with atypical features?. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 333-6	2.2	4
25	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2021 ,		4
24	White matter tract integrity is associated with antidepressant response to lurasidone in bipolar depression. <i>Bipolar Disorders</i> , 2017 , 19, 444-449	3.8	3
23	Electrophysiological predictors of clinical response to antidepressants380-393		3
22	Dysthymia and chronic depression20-36		3
21	Bromocriptine Treatment for Cocaine Addiction. <i>American Journal on Addictions</i> , 1993 , 2, 169-172	3.7	3
20	The Use of Monoamine Oxidase Inhibitors for Treating Atypical Depression. <i>Psychiatric Annals</i> , 2001 , 31, 371-375	0.5	3
19	Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder. <i>Journal of Affective Disorders</i> , 2019 , 245, 403-411	6.6	3
18	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial.. <i>Biological Psychiatry</i> , 2021 ,	7.9	3
17	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. <i>Journal of Affective Disorders</i> , 2019 , 256, 8-16	6.6	2
16	Cilobamine in the treatment of atypical depression. <i>Human Psychopharmacology</i> , 1988 , 3, 201-205	2.3	2
15	Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children. <i>Focus (American Psychiatric Publishing)</i> , 2016 , 14, 103-112	1.1	1
14	Pharmacological Management of Treatment-Resistant Unipolar Depression 2015 , 2311-2330		1
13	Co-occurring anxiety and depression: concepts, significance, and treatment implications90-102		1
12	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	0
11	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial.. <i>Journal of Psychiatric Research</i> , 2022 , 149, 243-251	5.2	0
10	Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials.. <i>Brain Communications</i> , 2022 , 4, fcac100	4.5	0
9	Management of adult major depressive disorder37-58		

8 Depression in the context of alcoholism and other substance-use disorders234-244

7 Atypical depression59-74

6 Complementary and alternative treatments for mood disorders245-257

5 Brain imaging358-367

4 Pharmacogenetics and mood disorders368-379

3 Treatment of Depression in Alcohol-Dependent Patients. *Disease Management and Health Outcomes*, **1997**, 2, 22-33

2 Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. *Focus (American Psychiatric Publishing)*, **2008**, 6, 104-119 1.1

1 Pharmacologic Management of Treatment-Resistant Unipolar Depression2372-2389